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Abstract
Background: Many consumers use natural health products (NHPs) concurrently with prescription medications. As NHP-
related harms are under-reported through passive surveillance, the safety of concurrent NHP-drug use remains unknown. To
conduct active surveillance in participating community pharmacies to identify adverse events related to concurrent NHP-
prescription drug use.
Methodology/Principal Findings: Participating pharmacists asked individuals collecting prescription medications about (i)
concurrent NHP/drug use in the previous three months and (ii) experiences of adverse events. If an adverse event was
identified and if the patient provided written consent, a research pharmacist conducted a guided telephone interview to
gather additional information after obtaining additional verbal consent and documenting so within the interview form. Over
a total of 112 pharmacy weeks, 2615 patients were screened, of which 1037 (39.7%; 95% CI: 37.8% to 41.5%) reported
concurrent NHP and prescription medication use. A total of 77 patients reported a possible AE (2.94%; 95% CI: 2.4% to
3.7%), which represents 7.4% of those using NHPs and prescription medications concurrently (95%CI: 6.0% to 9.2%). Of 15
patients available for an interview, 4 (26.7%: 95% CI: 4.3% to 49.0%) reported an AE that was determined to be ‘‘probably’’
due to NHP use.
Conclusions/Significance: Active surveillance markedly improves identification and reporting of adverse events associated
with concurrent NHP-drug use. Although not without challenges, active surveillance is feasible and can generate adverse
event data of sufficient quality to allow for meaningful adjudication to assess potential harms.
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Introduction
Recent national surveys in North America, Australia and
Europe suggest that more than half of the population uses dietary
supplements, also known as natural health products (NHPs) or
complementary medicines, including herbs, vitamins, minerals
and other supplements. [1–6] In developing countries, use is even
higher; in Africa for example, 80% of the population uses African
Traditional Medicine, 90% of which is plant-based. [5].
NHPs are generally considered to be safe by the public, despite
the growing evidence that this is not always the case. [1,7–11]
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Particular caution is warranted when NHPs are used in
combination with prescription medications due to the potential
for interactions. [1] Of note, NHPs are frequently used by patients
with chronic or recurrent conditions; these patients are also the
most likely to be prescribed conventional medications. [12–14]
Since the likelihood of an adverse event (AE), including drug
interactions, increases with the number of medicinal products
used, it is hypothesized that patients who concurrently use
prescription medications and NHPs are therefore at greater risk
for an AE than if they were using either product alone and
represent a population of particular interest with respect to
exploring the safety of NHPs. [10].
In most countries, the primary system of identifying post-
marketing AE related to therapeutic products is passive surveil-
lance (i.e., voluntary spontaneous reporting). [15] Increasingly,
these passive surveillance systems are also used for collecting
information about NHP-related AEs, as is the case in the United
States, Canada, the United Kingdom, Australia, and Germany.
[15–18] A strength of passive surveillance is its potential to identify
AEs from large populations that are using products under real
world circumstances, which should theoretically allow for the
identification of new and/or rare adverse events. [16,17].
Passive surveillance depends on voluntary reporting of adverse
events by health care practitioners (and, in some cases, patients)
and is known to be limited by substantial under-reporting with
estimates suggesting that perhaps less than 1% of AEs are ever
reported. [16–20] Patients may be even less likely to report AEs
associated with NHPs as compared to those associated with
conventional over-the-counter medications (OTC); some may not
associate NHPs with causing harms or may not consider NHP-
associated AEs important enough to report. [21,22] Among health
care providers, pharmacists have higher reporting rates, but like
other health professionals, they too under-report suspected NHP
AEs in comparison to those for conventional pharmaceuticals.
[19,23] This may be due to lack of awareness of their patients
NHP use: studies in the UK and Australia have found that
a majority of pharmacists does not ask customers about NHP use,
including when receiving reports of suspected AEs associated with
prescription medicines. [24,25] Similarly, physicians are poor at
reporting drug-related harms, and they do not routinely inquire
about their patients’ NHP use. [19,23,26] Combined, these patient
and health care provider factors suggest that passive surveillance
has important limitations with respect to identifying NHP-related
harms.
Another approach to investigating drug safety is active
surveillance which ‘‘seeks to ascertain completely the number of
adverse events via a continuous pre-organized process’’. [27]
Active surveillance methods are well-established for the collection
of adverse event data following prescription medicine use, [28,29]
but its application to pharmacovigilance of NHPs is limited to
date. Compared with passive surveillance, active surveillance
collects adverse event reports (i.e., harmful or unintended health
outcome which is not necessarily related to the use of a drug) and,
thus, achieves increased reporting rates, often with more
comprehensive, better quality reports. [27] A study designed to
improve AE reporting in a primary care setting specializing in
complementary and alternative medicine (CAM) demonstrated
a 148% increase in reporting. [30] Similarly, Al-Tajir and Kelly
found the incidence of adverse drug events associated with
prescription medications detected through active surveillance was
significantly higher (p,0.001) than for those reported spontane-
ously for both inpatients (3.592 vs. 0.068/100 patient days) and
outpatients (0.299 vs. 0.022/100 patient visits). [31].
Other forms of active surveillance of adverse events include
population-based administrative databases, such as British Co-
lumbia’s PharmaNet database, linked with hospitalizations and
health care use, and other computerized health-record databases,
such as the UK General Practice Research Database. [32,33]
However, these databases do not record NHP use and, therefore
are not useful at present for pharmacovigilance of this class of
products. [34].
While not an active surveillance study, community pharmacists
in a retrospective cross-sectional study in England were asked to
describe reports of suspected adverse reactions associated with
herbal medicines that they had identified or received (e.g. from
customers/patients) over the previous year. [24,34] In total,
among 818 respondents, 44 such reports were described (one per
19 pharmacists). [24,34] By contrast, in the national pilot scheme
in England for community pharmacist involvement in passive
surveillance that ran at the same time as the cross-sectional study,
among 3200 participant pharmacists, only 4 such reports were
submitted through passive surveillance (one per 800 pharmacists).
[35].
Since many NHPs are purchased in pharmacies in North
America, and since pharmacists are trained to recognize potential
product-related adverse reactions, including drug interactions,
pharmacies are an appropriate setting for an active reporting
model for NHP-related AEs. [19,21,36–38] The Study Of Natural
health product Adverse Reactions (SONAR) was a multi-centre
study assessing a community pharmacy-based active surveillance
system to identify NHP-drug interactions.
Methods
Research Ethics Board approval for this study was obtained
from both the University of Alberta and the University of Toronto.
Because there are quality issues with (at least, some) NHPs that
have an impact on safety, NHP-related harms can only be fully
interpreted with laboratory analysis of the implicated product(s) in
question. Therefore, we designed a two phase study, comprising
active surveillance and a causality assessment process that included
laboratory analysis to assess for contamination, adulteration and
NHP-drug interactions.
Phase I: Active Surveillance
The objective of this study was to use active surveillance in ten
community pharmacies in the Greater Toronto Area in Ontario,
Canada to identify AEs related to concurrent NHP-prescription
medication use. Participating pharmacies were selected using
convenience sampling to represent a range of pharmacy types
including: independent and chain pharmacies, pharmacies with
and without a special focus on NHPs, and outpatient hospital
pharmacies.
Participating pharmacy staff members were instructed to ask all
individuals collecting prescriptions for themselves or their child
about NHP use and concurrent NHP-prescription drug use in the
previous three months and the presence of any experiences of AEs
by using a standardized data form developed specifically for this
purpose. (Table 1) NHPs were defined using the Health Canada
definition as any medicinal product with active ingredients found
in nature and suitable for over-the-counter use including vitamins,
minerals, herbal remedies, homeopathic medicines, traditional
medicines, probiotics, amino acids and fatty acids. [39] If no NHP
use was identified in Question 1, no further questions were asked.
Three months was selected as the sampling frame as this
represents a typical time period between filling prescriptions for
chronic conditions to avoid repeated sampling from the same
SONAR: Active Surveillance in Community Pharmacies
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individuals. The pharmacy staff made no causality assessment of
a reported AE; all information was passed on for further
assessment. If an AE was identified, the patient was asked to
provide written consent to share his/her contact information with
a research pharmacist (KC) to schedule a follow-up telephone
interview. Verbal consent was obtained at the onset of the phone
interview. The interview collected details required for causality
assessment and information about the patient’s health state, all
products taken (prescription, over-the-counter (OTC) medications,
and NHPs) including brand and dose, hospitalizations and recent
medication changes. Patients were asked to describe what they felt
may have caused their AE; subsequently, independent experts
adjudicated the cases regardless of patient opinion. The patient
interview form was developed specifically for this purpose based on
the reporting requirements of Health Canada, the US Food and
Drug Administration, and the European Medicines Agency. [40–
42] A copy of the patient interview form is available from the
corresponding author upon request.
In order to prepare participating pharmacy staff members,
a training session was scheduled for each pharmacy to present the
study protocol and address questions or concerns. To further assist
pharmacists who might be faced with patients’ questions or
concerns regarding NHP-drug combinations and their effects,
a tool for quick identification of NHP-drug interactions was
developed and distributed to the participating pharmacists. [43]
Also, every pharmacy was given a textbook on NHPs as
a reference. [44] Finally, participating pharmacies were visited
regularly by study team members to address any issues and assist
with implementation of the data collection process.
Phase II: Causality Assessment and Laboratory Analysis
AE reports were developed based on telephone interviews and
assessed by our adjudicating committee, a three member panel
consisting of one NHP expert, one clinical expert, and the
committee chair, a clinician with expertise in pharmacology and
NHPs. The adjudicating committee assessed AE reports based on
the Naranjo algorithm, the Horn algorithm and World Health
Organization (WHO) causality assessment criteria. [45–47] The
adjudicating committee was asked to determine: (i) if there was
a causal relationship between the AE and any product the patient
was taking; (ii) if there was an NHP-drug interaction; and (iii) if
laboratory analysis was required. (Table 2) Three laboratories
were involved in evaluation of potential NHP-related harms: (i)
NHP constituent assessment; (ii) adulterant/contaminant evalua-
tion; and (iii) NHP-drug interaction evaluation (i.e. ability of NHP
to inhibit cytochrome P450-mediated metabolism). For their
analyses, the laboratories tested the actual products the patients
were taking when the AE occurred, as well as additional lots of the
products implicated to run comparative analyses.
Statistical Analysis
Analysis focused on Phase I data where proportions by
pharmacy and questionnaire version were calculated. A logistic
regression model with only an intercept term was used to provide
the weighted average proportion for each outcome and the
associated 95% confidence intervals (CIs). [48,49] SAS version 9.1
was used for all analyses. [50].
Results
Phase I: Active Surveillance
Participating pharmacies included five chain and four in-
dependent pharmacies, of which three self-proclaimed they
specialized in NHPs, as well as one hospital outpatient pharmacy.
The mean number of prescriptions filled daily in the participating
sites was 367 (range 70–1800). All pharmacy staff members agreed
to participate in the study (n= 29), including 17 pharmacists (10 of
whom were pharmacy managers or owners), 1 pharmacy intern, 2
pharmacy students, 6 pharmacy technicians, 2 nutritionists, and 1
store manager (who was not a pharmacist).
The first pharmacy was enrolled in March 2008, and data
collection was completed after a total of 112 pharmacy weeks.
Overall, 2615 patients were screened. Of these, 1037 reported
using NHPs and prescription medications concurrently (weighted
proportion= 39.7%; 95% CI: 37.8% to 41.5%). Among those
using NHPs and prescription medicines concurrently, 77 patients
reported experiencing AEs (weighted proportion= 7.4%; 95% CI:
6.0% to 9.2%). (Tables 3 and 4) Approximately one-third (36%;
n= 27) of patients who reported an AE originally agreed to be
contacted for the follow-up telephone interview. However, of
these, only 15 patients subsequently were interviewed, of whom 14
were recruited through the participating pharmacies and one was
referred to the study by her physician. Thirteen patients were not
interviewed for several reasons including: refusal to participate in
telephone interview (n= 6); lack of correct contact information
(n= 5); inability to adequately communicate in English via
telephone (n = 1); or lack of response despite multiple contact
attempts (n = 1). Detailed information was therefore collected in
23% of the suspected AE cases. Figure 1 provides a flow diagram
of numbers of participants progressing through the study.
Phase II: Causality Assessment and Laboratory Analysis
Following causality assessment of detailed telephone interviews,
4 of the 15 were adjudicated as ‘‘probably’’ related to patients’
NHP(s) use based on adjudication with the Naranjo and WHO
assessment scales. [45,47] In 3 out of 4 cases, the adjudicating
committee referred the products for laboratory analysis to evaluate
for probable NHP-drug interactions based on assessment using the
Horn scale. [46] Due to space constraints, only brief summaries of
the four case reports are discussed below; detailed reports are
Table 1. Pharmacy standardized patient screening form.
Screening Questions:
1. Are you currently using NHPs such as herbs, vitamins or other supplements, or have you used such products in the previous 3 months? (If NO, no additional
questions. If YES, proceed to #2).
2. Have you taken a prescription medication while also taking a NHP in the previous 3 months? (If NO, no additional questions. If YES, proceed to #3).
3. Have you experienced any unexpected or undesirable effects during the last 3 months? (If NO, no additional questions. If YES, proceed to #4).
4. Would you agree to be contacted by a pharmacist from our coordinating centre to conduct a telephone interview? (If NO, no additional questions. If YES, provide
study information sheet and document patient’s name, phone number, best time to call and patient’s signature)
doi:10.1371/journal.pone.0045196.t001
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published elsewhere for 2 of the 4 reports. One of these was
categorized as a serious AE because the patient required
hospitalization.
Overall, 11 of the 15 reports were considered unrelated to NHP
use. Eight of these cases were attributed to known adverse drug
reactions; examples including: muscle pain with atorvastatin;
nausea with extended-release tramadol XR (with positive
dechallenge); several generalized allergic reactions, e.g., urticarial
rash. In these cases, the NHP(s) had been used for a significant
period of time before the occurrence of the AE, while the suspect
drugs were changed or added in close proximity to the onset of
symptoms. Thus, there was a strong temporal association with the
suspect drugs, rather than the NHP(s). The remaining 3 cases were
inaccessible/unclassifiable due to an incomplete interview (n = 1),
inaccurate recall of the AE including dosing (n = 1) and question-
able details around the timeframe of the AE (n= 1). Summary
details of case reports with causality assessed as ‘‘probably’’ related
to NHP use follow. Table S1 summarizes data obtained from all
telephone interviews and their adjudication.
Case 1. A 19 year old male patient with depression,
neuropathic pain and delayed sleep phase disorder presented
after addition of melatonin to his current regimen of citalopram,
nortriptyline, and oxycodone with what he described as severe
sedation. Samples of the patient’s melatonin, together with
samples of another lot of the same product and of other melatonin
products, were all tested to show cytochrome P450 (CYP) 2C19
inhibitory activity in vitro. Because citalopram is metabolized by
CYP2C19, our study team suspects a combined pharmacody-
namic/pharmacokinetic mechanism of interaction which has not
previously been documented. (See File S1).
Case 2. A 38 year old female patient with hormone disorder
experienced fatigue, nervousness, heart palpitation, rash, and
muscle twitching following the addition of two blended herbal
products to her existing regimen comprising a multivitamin
containing green tea extract and a compounded progesterone
cream. The two blended multi-constituent products were screened
for their ability to inhibit CYP-mediated metabolism. Both
inhibited CYP2C19 and CYP2D6 activity in vitro and may,
therefore, have interacted with the constituents of the multivitamin
or progesterone products. [51].
Case 3. A 71 year old female with hypertension and
hypothyroidism reported symptoms of severe flushing after the
addition of niacin 1000mg once daily to her regimen of enalapril
10 mg and a compounded medication for her thyroid. The
flushing slowly improved once her physician ordered her to
discontinue the niacin and completely cleared after a period of
a few days. Lab analysis was not recommended for this case, as
flushing was recognized as a common side effect of niacin.
Case 4. A 53 year old female patient with asthma and who
also had symptoms related to menopause and depression/anxiety
was hospitalized for jaundice and fatigue and diagnosed with
hepatic necrosis. The patient was taking 13 different health
products, including several NHPs for weight loss and several
pharmaceuticals. Several products of both groups have been found
in an in-depth literature review to have hepatotoxic properties
(conjugated linoleic acid, GHRH, NutriMin CH, Softcap Fish OilH,
varenicline, venlafaxine). This case illustrates the potential dangers
of uncontrolled intake of multiple NHPs in combination with
prescription drugs without medical supervision. [52].
Discussion
In this study, we present one of the first prospective community-
based active surveillance studies to assess NHP related AEs and
NHP-drug interactions. Although not without its challenges, active
surveillance in pharmacies is feasible, and markedly increases both
the number and quality of AE reports in comparison to passive
surveillance. [53–56] When comparing our results to data derived
Table 2. Algorithm to assess the need for suspect products to undergo laboratory analysis.
1. Laboratory evaluation for potential pharmacokinetic
or pharmacodynamic interaction of the NHP
with prescription medications
2. Assessment for potential adulterants
or contaminants within the product
3. Issues related to product quality, whether
heterogeneity or pharmacological
actions of NHP components
Interactions between an NHP and drug assessed as
‘‘definite’’, ‘‘probable’’ or ‘‘possible’’
Causality of adverse events from NHP product
alone classified as being ‘‘possible’’ or higher
Causality of adverse events from NHP product
alone classified as being ‘‘possible’’ or higher
Unexpected increase or decrease in drug levels or
therapeutic effect of a previously stable drug; or difficulty in
achieving stable therapeutic effect or drug level in a newly
initiated drug
The NHP source was India, China or Mexico
(indicating a higher likelihood of contamination)
and causality for the report was classified as
being ‘‘probable’’ or ‘‘possible’’
NHP-drug combination has been identified as
yellow/orange/red (indicating a potential risk) in the
NHP-drug interaction tool [41]
NHP which is known to be often adulterated
with prescription drugs (e.g. NHPs for weight
loss, muscle enhancement, sexual enhancement
marketed as having anti-inflammatory properties)
and is causality for the report is classified as being
‘‘probable’’ or ‘‘possible’’
The product is well known to cause pharmacokinetic
and/or pharmacodynamic interactions with drugs/NHPs.
(Products with high index of suspicion: atazanavir,
betanaphthoflavone, carbamazepine, clarithromycin,
dexamethasone, digoxin, efavirenz, fluoxetine, fluvoxamine,
gemfibrozil, indinavir, insulin, isoniazid, itraconazole,
ketoconazole, lithium carbonate, methylcholanthrene,
modafinil, nafcillin, nefazodone, nelfinavir, nevirapine,
norethindrone, omeprazole, oxcarbazepine, paroxetine,
pentobarbital, phenobarbital, phenytoin, pioglitazone,
prednisone, quinidine, rifabutin, rifampin, ritonavir, saquinavir,
secobarbital, telithromycin, theophylline, troglitazone, warfarin)
doi:10.1371/journal.pone.0045196.t002
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from passive surveillance, we found that the Health Canada AE
database (Canada Vigilance) has a total of 1544 (median= 233.5,
range = 144 in 2004 to 442 as of December 31, 2009) AE reports
associated with NHP use over a five year period from passive
surveillance of over 30 million Canadians, which results in
a median incidence rate of approximately 0.0008%
(range = 0.0005% in 2004 to 0.0015% in 2009). [57] Given that
one third of Canadians report taking NHP and prescription
medications concurrently, the median incidence rate of AE reports
is approximately 0.0023% (range= 0.0014% in 2004 to 0.0044%
in 2009). [4] These values are far lower than AE rates reported by
individuals taking NHPs and drugs concurrently in the SONAR
study (7.4%; 95% CI: 6.0% to 9.2%), suggesting that active
surveillance improved AE reporting rates substantially. It is
important to note that the population screened in our study may
represent a different population than those screened through
passive surveillance. In particular, patients being screened in
a pharmacy may be more likely to take prescription medications;
since we hypothesized this may increase the risk of potential AEs,
this was the population of greatest interest to our study team.
Of note, without adjudication, it is not clear how many of the
AE reports from either active or passive surveillance are causally
linked to NHP use. In its surveillance system, Health Canada
applies a signal detection process to the incoming AE data
associated with all health products, including NHPs, and causality
assessment is conducted accordingly. However, often the quality of
AE reports is poor and important details allowing for proper
causality assessment are missing. [58].
Studies from several countries report that NHP use is extremely
common. While several have assessed concurrent use with
prescription medications, [59–61] few have reported on the
frequency of NHP-drug interactions associated with concurrent
use. In the 2002 Canadian National Health Population Survey,
21% of respondents had used both prescription medications and
NHPs in the previous year and 28.4% of those were using
combinations with potentially harmful interactions. [62] Data
collected from the 2002 United States Health and Diet Survey
Figure 1. Flow diagram of Phase I and II Results.
doi:10.1371/journal.pone.0045196.g001
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revealed that 4% of NHP users reported at least one adverse event
over the previous year. [59] In addition, those NHP users
reporting an AE were more likely to be taking prescription
medications and NHPs concurrently than those not reporting an
AE (74% vs. 58% respectively). [59] The population surveyed in
this study may differ in important ways from our urban
community pharmacy population which may partially explain
the differing AE rates.
While pharmacy-based active surveillance improved the quan-
tity and quality of AE reports, numerous challenges were
encountered. These included challenges in finding pharmacies
willing to participate and pharmacy staff members not screening as
many patients as expected. The most effective strategies to counter
these challenges were involvement of pharmacy staff with previous
research experience, involving recent graduates and students in
data collection, as well as close contact and frequent visits to the
sites to ensure implementation of the study protocol. This pilot
program involved pharmacies/pharmacists who volunteered to
participate in NHP safety research and, therefore, may not be
representative of all pharmacies/pharmacists in Canada. On the
other hand, this was an entirely new concept – for pharmacists to
take responsibility for adverse event reporting (and with our
results, perhaps more pharmacists will be interested in NHP
adverse events).
Potential sampling bias also extended to the consumers
screened. Only those sufficiently healthy enough to collect their
or their child’s prescriptions from the pharmacy were screened.
Limiting screening to outpatient community pharmacies mini-
mizes the ability to identify current AEs requiring hospitalization
or past AEs resulting in hospitalization or even death. In addition,
since the pharmacy sites screened fewer patients than was
originally expected, it is possible the choice of who to screen was
biased in some way. Pharmacy participants stated that patient
screening depended on workload. However this was difficult to
quantify: limited data were provided to us on the number of
prescriptions filled by each pharmacy during the study period, but
this number is likely to be much lower than the number of
consumers served. Recall bias with respect to patient reports of
AEs was another limitation. When possible, hospital records and
laboratory data were collected to ensure the highest level of
accuracy. Reassuringly, our study found rates of NHP use and
NHP-drug concurrent use similar to those reported by others,
suggesting that our sampling frame was acceptable. [2,63–65] In
this study, the AEs were identified by patients in an out-patient
setting rather than by clinicians or other health professionals,
which is more typical of some active surveillance designs. While
this limited the data available to investigate the AE, such as
obtaining drug/NHP plasma concentrations, our approach helped
overcome several major obstacles in detecting NHP-related harms,
namely lack of inquiry about NHP use, lack of inquiry about
experiences of harms, and lack of reporting, even if harms are
identified.
The community setting offered a key strength to our design:
SONAR screened a comparatively large sample of patients who
were using NHPs under real-world conditions. The study resulted
in the development of a practical tool (the NHP-drug interaction
tool), [43] that has been published and has since been in use by
a number of clinicians who have confirmed its usefulness. To our
knowledge, SONAR is the first to systematically capture NHP-
drug interactions by identifying clinically relevant harms first,
coupled with basic science investigation to examine the plausible
mechanism. More often in the literature, NHP-drug interactions
have been posited on theoretical grounds but their clinical
relevance remains unknown, as these harms have not been
identified in clinical practice. [66–68] Although follow-up inter-
views were difficult to schedule, the quality of data obtained
allowed meaningful adjudication: all cases deemed to be ‘‘prob-
ably’’ NHP related, and referred for lab analysis for evaluation of
NHP-drug interaction, had confirmatory lab findings. Strength of
our design was the opportunity to investigate the mechanism of
action of NHP AEs through laboratory research, promoting the
detection of novel clinically relevant NHP-drug interactions. It is
important to note that with a greater degree of AE reporting
comes a greater possibility of loss to follow-up, and this is an
important limitation in conducting active surveillance. Further
studies should investigate the sensitivity and specificity of the
adjudication process, as well as methods to improve follow-up in
active surveillance of NHP-related harms.
Serious harms tend to be rare, and their detection is extremely
challenging. Harms assessment is a multistage process: product use
must be disclosed and discussed; product-related harms must be
Table 3. Proportion of concurrent use of NHP and






ON01 439 174 39.6%
ON02 189 67 35.5%
ON03 502 232 46.2%
ON04 249 132 53.0%
ON05 340 72 21.2%
ON06 137 44 32.1%
ON07 11 4 36.4%
ON08a 25 7 28.0%
ON08b 168 74 44.1%
ON09 211 60 28.4%
ON10 344 171 49.7%
Total 2615 1037 39.7%
doi:10.1371/journal.pone.0045196.t003
Table 4. Proportion with adverse events for those









ON01 174 10 5.8%
ON02 67 1 1.5%
ON03 232 16 6.9%
ON04 132 6 4.6%
ON05 72 0 0.0%
ON06 44 1 2.3%
ON07 4 0 0.0%
ON08a 7 1 14.3%
ON08b 74 10 13.5%
ON09 60 11 18.3%
ON10 171 21 12.3%
Total 1037 77 7.4%
doi:10.1371/journal.pone.0045196.t004
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consistently included in the differential diagnosis; suspected harms
must be reported in sufficient quantity and quality for signal
detection to occur. Active surveillance offers means to promote
discussion and allows for meaningful adjudication, and, therefore
offers an important contribution to patient safety and pharma-
covigilance. It is difficult to determine causality of an AE if
potential drug interactions, product authenticity adulterants/
contaminants and NHP components are not investigated simul-
taneously. [69] The paucity of literature regarding the risks
involved with NHP use is not enough reason to consider these
products ‘‘safe’’. [70] Only systematic data collection and analysis
will provide the necessary evidence to consider an NHP safe,
particularly in the context of concurrent use with prescription
medications.
In practice, although clinicians and patients can tolerate certain
degrees of uncertainty surrounding effectiveness (i.e. a therapeutic
trial or ‘‘try-and-see’’ approach), they are understandably less
tolerant of uncertainty surrounding safety. We found 7% of those
concurrently using NHPs with medications report AE, with 4/15
(26.7%; 95% CI: 4.3% to 49.0%) probably due to NHP use;
whether or not this is interpreted as low or high depends on one’s
perspective.
Within Canada, provincial electronic health databases exist to
facilitate active surveillance by capturing adverse event informa-
tion relating to prescription drugs as they occur. [32] Although
these databases may have the ability to capture NHP and over-
the-counter drug data, this is not widely known and thus they are
therefore still limited in their ability to actively capture AEs within
this scope of product use. [34].
Our study provides a novel method for investigating harms
relating to NHPs to assess causality and provide clinical evidence
for future patients. Active surveillance improved detection and
reporting, and the rigorous investigation of detected harms
generates clinical evidence to allow for practice-based change,
promoting patient safety. Additional work is needed to establish if
active surveillance is cost effective. According to a Health Council
of Canada publication, the annual operating costs for the
Marketed Health Products Directorate was $23.6 M for the year
ending March 31, 2010 and is anticipated to be $30.5 M for the
year ending March 31, 2012; MHPD has confirmed that
approximately 10% of their budget is spent on NHP surveillance
activities. [71] (See File S2) Our research team was able to start the
first NHP AE active surveillance program for approximately 1% of
the MHPD NHP budget. Further research is required to
determine the potential economic impact of implementing active
surveillance on a wider scale.
In conclusion, active surveillance for NHP-related AEs in
community pharmacies is feasible. Further investigation of its
potential contributions to assessment of NHP safety is warranted.
Future research includes the addition of NHP AE screening within
already developed provincial electronic health databases, and the
use of both active surveillance and causality assessment in high risk
populations, such as those seen in hospital subspecialty clinics.
There is also an opportunity to test the utility of active surveillance
in other countries that regulate NHPs, as it may prove informative
for both NHP and drug-related adverse events based on real-world
use. The limitations of passive surveillance have been well
documented, but the potential advantages of active surveillance
have yet to be fully explored.
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